Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Autor: Philip N. Newsome, Stephen Harrison, Sven Francque, Vlad Ratziu, Morten Rix Hansen, Arun J. Sanyal, Martin Linder, Salvatore Calanna, Luc Van Gaal
Rok vydání: 2019
Předmět:
Male
Glucagon-Like Peptides
Impact of Semaglutide on Liver Enzymes and Inflammation in Type 2 Diabetes and Obesity
Type 2 diabetes
Gastroenterology
Glucagon-Like Peptide 1
Non-alcoholic Fatty Liver Disease
Weight management
Multicenter Studies as Topic
Pharmacology (medical)
Randomized Controlled Trials as Topic
Aged
80 and over
Pharmacology. Therapy
Fatty liver
Alanine Transaminase
Middle Aged
Weight Reduction Programs
Liver
Cardiovascular Diseases
Original Article
Female
Adult
medicine.medical_specialty
Adolescent
Placebo
Young Adult
Clinical Trials
Phase II as Topic
Double-Blind Method
Internal medicine
Diabetes mellitus
medicine
Humans
Hypoglycemic Agents
Obesity
Aged
Retrospective Studies
Inflammation
Hepatology
business.industry
Semaglutide
Body Weight
medicine.disease
digestive system diseases
Clinical trial
Clinical Trials
Phase III as Topic
Diabetes Mellitus
Type 2
Human medicine
business
Biomarkers
Zdroj: Alimentary pharmacology and therapeutics
Alimentary Pharmacology & Therapeutics
ISSN: 0269-2813
DOI: 10.1111/apt.15316
Popis: Background Obesity and type 2 diabetes are drivers of non-alcoholic fatty liver disease (NAFLD). Glucagon-like peptide-1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. Aim To evaluate the effect of the glucagon-like peptide-1 analogue, semaglutide, on alanine aminotransferase (ALT) and high-sensitivity C-reactive protein (hsCRP) in subjects at risk of NAFLD. Methods Data from a 104-week cardiovascular outcomes trial in type 2 diabetes (semaglutide 0.5 or 1.0 mg/week) and a 52-week weight management trial (semaglutide 0.05-0.4 mg/day) were analysed. Treatment ratios vs placebo were estimated for ALT (both trials) and hsCRP (weight management trial only) using a mixed model for repeated measurements, with or without adjustment for change in body weight. Results Elevated baseline ALT (men >30 IU/L; women >19 IU/L) was present in 52% (499/957) of weight management trial subjects. In this group with elevated ALT, end-of-treatment ALT reductions were 6%-21% (P= 0.2 mg/day) and hsCRP reductions 25%-43% vs placebo (P < 0.05 for 0.2 and 0.4 mg/day). Normalisation of elevated baseline ALT occurred in 25%-46% of weight management trial subjects, vs 18% on placebo. Elevated baseline ALT was present in 41% (1325/3268) of cardiovascular outcomes trial subjects. In this group with elevated ALT, no significant ALT reduction was noted at end-of-treatment for 0.5 mg/week, while a 9% reduction vs placebo was seen for 1.0 mg/week (P = 0.0024). Treatment ratios for changes in ALT and hsCRP were not statistically significant after adjustment for weight change. Conclusions Semaglutide significantly reduced ALT and hsCRP in clinical trials in subjects with obesity and/or type 2 diabetes.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje